More recently, 99mTc-EDDA/HYNIC-TOC(Tektrotyd) was introduced into the market and its use has been approved for imaging of patients with L-NETs and other SSTR-positive tumors. 99mTc-EDDA/HYNIC-TOC could also represent a good alternative to 68Ga-DOTA-peptides (DOTA-TOC, DOTA-NOC, DOTATATE...
MIRD)方法,基于99mTc-HYNICTOC在人体内的分布,利用内照射计算软件 OLINDA/EXM及GE Dosimetry Toolkit计算其在5例没有明显异常浓聚灶的神经内分泌肿瘤患者体内各器官的吸收剂量、全身吸收剂量及全身有效剂量,为临床安全使用99mTc-HYNIC-TOC提供依据。
全身平均单位活度吸收剂量男性为0.001 7 mGy/MBq,女性为0.001 6 mGy/MBq.全身单位活度有效剂量男性为0.004 58 mSv/MBq,女性为0.004 55 mSv/MBq.结论:99mTc-HYNIC-TOC可安全 地用于人体,其有效剂量低于允许范围上限.该研究结果可为临床安全使用99mTc-HYNIC-TOC提供依据,也为其他放射性药 物的安全性评估和加快临床...
Tc-HYNIC-TOC SPECT/CT检出最小病灶最 大径仅7 mm ,T/NT值达2.68 。此外,全身平面显像配合SPECT/CT 断层显像可更准确发现更多肝内转移灶,对肝转移灶 疗效评价也有较好的应用价值。 结论 99mTc-HYNIC-TOC SPECT/CT 显像可准确、灵敏地探测肝转移灶。 99mTc-HYNIC-TOC 显像;神经内分泌肿瘤;肝转移 【关键词】...
Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC- TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1635-45Czepczynski R, Parisella MG, Kosowicz J, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with ...
99mTc-HYNIC-TOC SPECT/CT显像探测结直肠神经内分泌肿 瘤的临床价值 李毅1,2,徐俊彦1,2,3,4,许晓平1,2,3,4,张建岗1,2,3,马光1,2,胡四龙1,2,3,4,潘禾戎1,2,3, 程竞仪1,2,3,4,章英剑1,2,3,4 1. 复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海 200032; 2. 复旦大学生物...
1.2 检查方法 1.2.1 药物制备 99mTc-HYNIC-TOC由本科制备[3]。简述如下:20μg HYNIC-TOC(德国ABX公司)加入 0.5 mL 乙二胺乙二酸(ethylenediaminediacetate, EDDA)溶液(20 mg/mL,溶于0.1 mol/L NaOH溶液)和0.5 mL Tricine溶液[40 mg/mL,溶于0.2 mol/L pH值为6的磷酸盐缓冲液(phosphate buffered saline, ...
[99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-Ocreotide (99mTc-EDDA-HYNIC-TOC) increasingly emerges to be an alternative tool for somatostatin receptor (SSTR) scintigraphy of neuroendocrine tumours. The high quality of this radiopharmaceutical and its uniformity are very important facts for application of this...
此外,在本申请的放射性药物的结构中,hynic还起到生物识别位点与放射性金属之间的间隔物的作用,而在其他放射性药物中,hynic专门用作用于由99mtc进行标记的双功能试剂[decristoforocetal.99mtc-edda/hynic-toc:anew99mtc-labelledradiopharmaceuticalforimagingsomatostatinreceptor-positivetumours;firstclinicalresultsandintra-patie...
Preparation via coligand exchange and characterization of [99mTc〦DDA〩YNIC〥㏄he1,Tyr3]Octreotide (99mTc–EDDA/HYNIC–TOC) 99m Tc-EDDA–HYNIC-D-Phe 1 ,Tyr 3 ]octreotide ( 99m Tc-EDDA/HYNIC–TOC) is a promising new agent with the potential to replace [ 111 In-DTPA-D-Phe 1 ]-oct...